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ABSTRACT
Objective: Objective of the present investigation is to develop a speedy isocratic reverse phase high-performance liquid chromatography (RP-
HPLC) method for the separation and quantitative determination of 5 angiotensin II - receptor antagonists, namely, telmisartan, losartan, valsartan, 
olmesartan, irbesartan, and atenolol along with thiazide diuretics mostly hydrochlorothiazide (HCTZ).
Methods:  RP-HPLC method was evolved using Welchrom C18 column (4.6 × 250 mm, 5 µm) as a stationary phase with the mobile phase comprising a 
variety of phosphate buffer with pH-3.3 and acetonitrile in the proportion of 50:50 v/v. The mobile phase was pumped at a current rate of 1 mL/minute. 
The detection wavelength was carried out at 230 nm.
Results: The total run time was 6 minutes and the elution window of only 3 minutes. The peaks were eluted with decorous resolution. The calibration 
curves were linear (r2=0.9998) in all cases. The percentage relative standard deviation (RSD%) was <2% and average recovery was above 99.95%. 
The method was validated specificity, precision, and accuracy. High recovery values and low RSD% prove that this method is very accurate and 
reproducible. The developed method was applied to the estimation of the above-said drugs in binary combinations from different manufacturers 
which were a good agreement with label claim.
Conclusion: The important advantage of developed method was that the five individual drugs can be determined on a single chromatographic system 
without alteration in detection wavelength and mobile phase composition. This novel method was statistically validated as per ICH guidelines. The 
optimized method proved to be linear, accurate, and robust. Hence, the above said proposed method was found to be a rapid tool for the routine 
determination of the above-said drugs in alone or combination with HCTZ in quality control analysis without interference of excipients.
Keywords: Telmisartan, Losartan, Valsartan, Olmesartan, Irbesartan, Atenolol, Reversed-phase high-performance liquid chromatography.
INTRODUCTION
Angiotensin antagonists are the first major innovation in essential 
hypertension management as a first-line treatment. Antihypertensive 
agents are a largest drug class and hold a major share of the drug 
market, as hypertension is a major cause of health problems. 
Hydrochlorothiazide (HCTZ) acts on both RAS and sympathetic nerve 
system, thereby creating greater sensitivity to angiotensin receptor 
blockade (ARBs). This HCTZ is a good selection for use in combination 
with ARBs. ACE inhibitors are having major problems of cough, when 
compared to ARBs. All the existing ARBs and atenolol (ATEN) are in 
fixed-dose combination with HCTZ. According to the available present 
knowledge, no unique single reversed-phase high-performance liquid 
chromatography (RP-HPLC) method available for the determination 
of 5 angiotensin II-receptor antagonists, i.e. ATEN, telmisartan 
(TELM), losartan (LOSA), valsartan (VALS), olmesartan (OLME), and 
irbesartan (IRBE) along with thiazide diuretics mostly HCTZ. The 
present proposed method will help in determination of drugs in a 
single run, which reduces the analysis time and does not necessarily 
any separate method for each drug and combined tablet formulation. 
After a meticulous survey of literature reveals that there were some 
analytical methods have been reported for the determination of the 
drugs either individually or in combination with some additional drugs 
in tablet dosage forms and biological samples based on a wide variety 
of instruments such as spectrophotometric method [1], capillary 
electrophoresis [2], HPLC [3-16], LC-mass spectrometry (MS) [17,18], 
and LC-MS/MS [19-21]. Keeping in view of the complete evaluation the 
authors aim to develop a novel, simple, accurate, and sensitive method 
to determine combinations such as HCTZ with ATEN, HCTZ with TELM, 
HCTZ with LOSA, HCTZ with VALS, HCTZ with OLME, and HCTZ with 
IBRE without altering the detection wave length and chromatographic 
conditions.
METHODS
The above said standard drugs were gifted from Hetero Labs Ltd., 
Hyderabad, India. All other chemicals used in this method were 
purchased from Merck Chemical Division Ltd., Mumbai. HPLC grade 
acetonitrile, water, methanol, and triethylamine were obtained from 
Merck Pharmaceuticals Private Ltd., Mumbai, India. Commercial tablets 
of the above said formulation were procured from local pharmacies.
Apparatus and instruments
RP-HPLC was done on an isocratic HPLC (Shimadzu LC-20AT 
prominence LC) with a LC-20AT pump, manual Rheodyne injector 
with a loop volume of 20 µl, variable wavelength Shimadzu SPD-20 
A prominence ultraviolet (UV) detector, and Welchrom C18 Column 
(4.6 × 250 mm, 5 µm particle size). The HPLC system was set with “Spin 
chrome” software. An electronic balance (Shimadzu TX223L), digital 
PH meter (Systronics model - 802), a sonicator (spectral lab, model 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i12.18714.
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UCB 40), and UV-Visible spectrophotometer (Systronics model-2203) 
were used in this analysis.
Preparation of pH 3.3 phosphate buffer
A 10 mM phosphate buffer was prepared by dissolving 6.056 g of 
potassium dihydrogen ortho phosphate in 445 ml of HPLC grade water. 
To this 55 ml of 0.1 M phosphoric acid was added and the pH was 
adjusted to 3.3.
Preparation of mobile phase
The above prepared buffer and acetonitrile were mixed in the proportion 
of 50: 50 v/v and were filtered through 0.45 µm nylon membrane filter 
and degassed by sonication
Preparation of stock standard solutions and calibration plot
Stock standard solutions containing 1.25, 0.25, 0.4, 0.5, 0.4, 0.8, and 
1.5 mg/ml of HCTZ, ATEN, TELM, LOSA, VALS, OLME, and IRBE, 
respectively, were prepared by dissolving 12.5, 25, 40, 50, 40, 80, 
and 150 mg of each in the mobile phase in a 100 ml volumetric flask, 
respectively. It was then sonicated for 20 minutes and the eventual 
volume of the solutions was filled up to 100 ml with methanol to get 
stock standard solutions. To construct calibration plots, the stock 
standard solutions were diluted with the mobile phase to prepare 
working solutions to get various concentrations ranging from 2.5-12.5, 
5-25, 8-40, 5-50, 8-40, 16-80, and 30-150 µg/ml for HCTZ, ATEN, TELM, 
LOSA, VALS, OLME, and IRBE, respectively.
Sample preparation
Twenty tablets of each sample Atenova-H (25 mg/tab ATEN), Cresar-H 
(40 mg/tab TELM), Hyzaar (50 mg LOSA), Valfect-H (40 mg VALS), 
Olmax-H (80 mg OLME), and Irovel-H (150 mg IRBE) and all these 
samples contains 12.5 mg/tab of HCTZ were weighed accurately and 
average weight was determined. The contents were ground into a 
fine powder and the powder equivalent to 100 milligrams of the drug 
was transferred in to a 100 ml of calibrated flask and dissolved in 
70 ml of mobile phase with vigorous shaking and extracted 2 times 
with 10 ml portions of mobile phase and filtered through Whatman 
quantitative filter paper grade 41 into a 100 ml volumetric flask and 
diluted up to the mark with the same. From the above filtrate, 1 ml 
was further transferred to 100 ml volumetric flask and made up to 
the mark with mobile phase to obtain 100 µg/ml sample solution in 
each case. These prepared solutions were utilized as stock sample 
solutions throughout the work. Subsequent dilution of this solution 
was prepared with mobile phase to furnish the above-mentioned 
concentrations. The diluted solutions were analyzed under optimized 
chromatographic conditions employed and chromatogram is shown 
in Fig. 1.
Method optimization
When developing a novel method one of the most important goals is 
to accomplish a consistent reproducible separation. To acquire correct 
optimized HPLC conditions in the first instance in isocratic mode, 
copious trails were carried out by varying the different solvent mixtures 
such as acetonitrile, methanol, HPLC grade water, with or without 
buffers in different combinations, C18, C8 columns, and flow rates as well 
as pH of were tested. Based on the nature of the drugs eventually C18 
column was chosen as a stationary phase. Trials of optimization were 
made by varying one parameter at a time, keeping all other parameters 
constant. Ultimately decorous resolution, short run time, excellent peak 
shape, minimal peak tailing, and good reproducibility results were 
identified when an analytical column of C18 and a mixture of mobile 
phase consisting phosphate buffer with pH 3.3 and acetonitrile in the 
ratio of 50:50 v/v, using a flow rate of 1mL/min are found to be suitable 
for most combinations. Optimized chromatographic conditions and 
system suitability parameters are shown in Table 1. UV overlain spectra 
of the ATEN and five separations with HCTZ are shown in Fig. 2.
Method validation
The developed method of analysis was validated in pursuance of the 
guidelines of ICH Q2 (R1) [22,23] to examine the parameters such 
as system suitability, linearity, specificity, precision, accuracy, and 
robustness, limit of detection (LOD), and limit of quantitation (LOQ).
RESULTS AND DISCUSSION
In the present study drug solutions of 10 µg/mL concentration 
solution of ATEN, HCTZ, TELM, LOSA, VALS, OLME, and IRBE were 
separately prepared with the mobile phase. All the seven drugs 
were scanned over the range of 200-400 nm in spectrum mode by 
applying UV spectrophotometer. By studying the overlain spectra, it 
was observed that all these four drugs showed optimum absorbance 
at 230 nm and were selected for further study. Accordingly, system 
suitability parameters such as retention time, resolution, the number 
of theoretical plates, efficiency/meter, and tailing factor of the peaks 
were computed for the optimized chromatographic conditions. As a 
result retention time of 2.431, 3.077, 3.230, 4.030, 5.243, 4.463, and 
5.563 minutes, resolution of --, 3.354, 2.615, 2.755, 2.844, 3.675, 
and 2.057 for ATEN, HCTZ, TELM, LOSA, VALS, OLME, and IRBE were 
obtained. Moreover, the plate number of 11987, 12865, 13379, 14567, 
15231, 15625, and 16058 was obtained for ATEN, HCTZ, TELM, LOSA, 
VALS, OLME, and IRBE and tailing factors of 1.164, 1.146, 1.128, 1.164, 
1.143, 1.150, and 1.132 were obtained for ATEN, HCTZ, TELM, LOSA, 
VALS, OLME, and IRBE, respectively. As the results obtained were 
within the satisfactory limits, this method is apt for the separation and 
estimation of the above said drugs. Summary of validation parameters 
linearity, specificity, precision, accuracy, LOD, and LOQ is shown in 
Table 2.
Linearity
The purpose of this study is to verify that the detector response is 
directly proportional to the concentration of analyte in the sample. 
Linearity of developed method was determined by taking five different 
concentrations. The calibration curves for seven different drugs 
showed linearity over a concentration range of 5-25, 2.5-12.5, 8-40, 
5-50, 8-40, 16-80, and 30-150 µg/mL for ATEN, HCTZ, TELM, LOSA, 
VALS, OLME, and IRBE, respectively. In ATENOVA - H 25 mg tablet 
Fig. 1: A typical chromatogram showing the separation of atenolol 
and five angiotensin receptor blockade in the presence of 
hydrochlorothiazide mixture
Fig. 2: Ultraviolet overlain spectra of the atenolol and five sartans 
with hydrochlorothiazide
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5-25 µg/mL and 2.5-12.5 µg/mL for HCTZ; Cresar - H 40 mg tablet 
8-40 µg/mL for TELM and 2.5-12.5 µg/mL for HCTZ; for Hyzaar 50 mg 
tablet 5-50 µg/mL for LOSA and 2.5-12.5 µg/mL for HCTZ; for Valent-H 
80 mg tablet 16-80 µg/mL for VALS and 2.5-12.5 µg/mL for HCTZ; 
Olmax-H 40 mg tablet 8-40 µg/mL for OLME and 2.5-12.5 µg/mL for 
HCTZ; Irovel-H 150 mg tablet 30-150 µg/mL for IRBE 2.5-12.5 µg/mL 
for HCTZ and the correlation coefficients were calculated from the 
linear regression analysis and it was found to be above 0.9998 in all 
cases. The obtained results were satisfactory as there exist a significant 
correlation between concentrations of each drug and their peak areas. 
The r2 (correlation coefficients) regression was found almost equal to 
one in all cases.
Specificity
The purpose of this study is to evaluated by determine the effect of 
excipients, additives present in the formulations interfered with the 
analysis or not. As per the ICH guidelines, to test the specificity of the 
developed method a combination of pure drug samples with proper 
excipients were injected to the system for quantifying each drug 
individually and also in combination of two drugs, namely, HCTZ with 
ATEN and HCTZ with TELM, HCTZ with LOSA, HCTZ with VALS, HCTZ 
with OLME, and HCTZ with IRBE. In the same way blank solution with 
only commonly utilized excipients and synthetic mixture solutions 
were also injected separately. Peak responses for analyte and the blank 
were compared with each appropriate drug. The present study shows 
that there is no commonly used excipients are interfering with the drug 
peaks. Thus, the method clearly proves to be specific for determining 
the above said drugs.
Precision
To check the reproducibility of the method, the precision of the 
analytical method was determined by using intraday and interday 
studies. Triplicate samples of standard quality were taken in varying 
concentration levels and estimated for the intraday and interday 
precision of the developed method. For repeatability and intermediate 
precision the relative standard deviation (RSD%) values for all the 
drugs were calculated and RSD% of all the combined drugs were shown 
<2% which explains that the current method is precise.
Accuracy
Accuracy of the present method was evaluated by combining the known 
quantity of pure standard drugs to pre analyzed samples at three 
different levels mostly 80%, 100%, and 120%. Then, the recovery levels 
were observed obviously. The above-mentioned solutions were again 
prepared and analyzed in triplicate carefully. The same procedure was 
followed for all the individual drugs and also for drug combinations 
such as HCTZ with ATEN and HCTZ with TELM, HCTZ with LOSA, HCTZ 
with VALS, HCTZ with OLME, and HCTZ with IRBE and RSD% calculated 
was also known to be <2% for each of the drugs. As per ICH guidelines 
the % recovery must be between 98% and 102%.
Robustness
Small, experimental conditions such as flow rate, detection wavelength, 
and mobile phase composition are deliberately changed. It was observed 
in fact no significant variations in these parameters indicating that the 
method is robust. The RSD% values obtained in all the cases are <2%, 
hence this method is robust. Table 3 summarizes the robustness, data.
Table 1: Optimized chromatographic conditions and system suitability parameters
Parameter Chromatographic conditions for four sartans and hydrochlorothiazide
Instrument Shimadzu LC-20AT prominence LC
Column Welchrom C18 column (4.6×250 mm, 5 µm)
Detector Shimadzu SPD-20A prominence UV-VIS detector
Mobile phase 10 mM phosphate buffer (pH 3.3): Acetonitrile 50:50, v/v
Flow rate 1 mL/min
wave length UV at 230 nm
Run time 6 minutes
Temperature Ambient temperature (25°C)
Injection volume 20 µL
ATEN HCTZ TELM LOSA VALS OLME IRBE
Retention time (minute) 2.431 3.077 3.230 4.030 5.243 4.463 5.563
Th.Pl (efficiency) 11.987 12.865 13.379 14.567 15.231 15.625 16.058
Resolution - 3.354 2.615 2.755 2.844 3.675 2.057
Tailing factors 1.164 1.146 1.128 1.164 1.143 1.150 1.132
LC: Liquid chromatography, UV-VIS: Ultraviolet-visible, ATEN: Atenolol, OLME: Olmesartan, HCTZ: Hydrochlorothiazide, TELM: Telmisartan, LOSA: Losartan, 
VALS: Valsartan, IRBE: Irbesartan
Table 2: Summary of validation parameters
Formulation 
(tablets)













ATENOVA-H ATEN 5-25 0.331 and 1.02 99.95±1.24 99.92±0.67 0.343 0.342
HCTZ 2.5-12.5 0.285 and 0.940 98.75±0.16 99.82±0.12 0.167 0.162
Cresar-H TELM 8-40 0.565 and 1.86 99.97±1.12 100.09±0.71 0. 127 0.167
HCTZ 2.5-12.5 0.298 and 0.980 98.14±0.32 100.05±0.16 0.132 0.324
Hyzaar LOSA 5-50 0.197 and 0.650 99.87±0.12 99.98±0.42 0.467 0.472
HCTZ 2.5-12.5 0.296 and 0.981 99.14±0.31 100.06±0.19 0.188 0.182
Valfect-H VALS 8-40 0.731 and 2.414 99.88±1.14 100.02±0.16 0.342 0.324
HCTZ 2.5-12.5 0.297 and 0.980 98.18±0.42 99.98±0.12 0.127 0.432
Olmax-H OLME 16-80 1.198 and 3.953 99.99±1.12 100.45±0.40 0.432 0.654
HCTZ 2.5-12.5 0.295 and 0.980 99.15±0.12 99.97±0.13 0.168 0.324
Irovel-H IRBE 30-150 1.220 and 4.026 100.15±1.30 100.47±0.4 0.467 0.324
HCTZ 2.5-12.5 0.296 and 0.980 99.59±0.12 99.96±0.15 0.213 0.435
LOD: Limit of detection, LOQ: Limit of quantitation, SD: Standard deviation, IRBE: Irbesartan, HCTZ: Hydrochlorothiazide, ATEN: Atenolol, OLME: Olmesartan, 
LOSA: Losartan, VALS: Valsartan, TELM: Telmisartan
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LOD and LOQ
Sensitivity of the analytical method is evaluated by the LOD and 
LOQ. LOD=3.3 (SD)/S and LOQ=10 (SD)/S. The LOD and LOQ 
results for combined drugs such as ATEN with HCTZ, TELM 
with HCTZ, LOSA with HCTZ, VALS with HCTZ, OLME with 
HCTZ, and IBRE with HCTZ were found to be 0.331μg/mL and 
1.026 μg/mL, 0.285 μg/mL and 0.940 μg/mL; 0.565 μg/mL and 
1.86 μg/mL, 0.298 μg/mL and 0.980 μg/mL; 0.197 μg/mL and 0.650 
μg/mL, 0.296 μg/mL and 0.981 μg/mL; 0.731 μg/mL and 2.414 μg/mL, 
0.297 μg/mL and 0.980 μg/mL; 1.198 μg/mL and 3.953 μg/mL, 0.295 
μg/mL and 0.980 μg/mL; 1.220 μg/mL and 4.026 μg/mL, and 0.296 
μg/mL and 0.980 μg/mL, respectively. The lowest LOD and LOQ values 
showed that the method is more sensitive.
Assay
The developed method was finally applied for quantification of marketing 
formulation. Satisfactory results have been obtained. The mean assay 
values for ATEN with HCTZ, TELM with HCTZ, LOSA with HCTZ, VALS 
with HCTZ OLME with HCTZ, and IBRE with HCTZ combination of 
drugs were found to be 99.95±1.24 and 98.75±0.16; 99.97±1.12 and 
98.14±0.32; 99.87±0.12 and 99.14±0.31; 99.88±1.14 and 98.18±0.42; 
99.99±1.12 and 99.15±0.12; 100.15±1.30 and 99.59±0.12, respectively. 
The mean assay values were in good agreement with the label claim 
(Table 2). Hence, by the developed method all the specified drugs 
were recovered perfectly pharmaceutical dosage forms. Therefore, the 
method developed was found to be properly suitable for the estimation 
of the marketed formulations.
CONCLUSION
A simple, precise, accurate, and sensitive isocratic RP-HPLC method 
have been developed for simultaneous determination of HCTZ, ATEN, 
TELM, LOSA, VALS, OLME, and IRBE in bulk and combined tablet 
dosage forms. Statistical analysis lucidly proves that this method is fast, 
cost effective, highly efficient, and robust than the existing methods 
hitherto. In addition, to that, the method is free from interferences of 
the excipients and additives used in the preparation of the above-said 
combination formulations. This novel method separated all the above-
said drugs in 4 minutes and total run time of just 6 minutes and it is 
also feasible for analysis of said angiotensin receptor blockades with 
HCTZ in their formulations in a single run without changing the mobile 
phase composition and chromatographic conditions. Hence, it is correct 
to conclude that it is effectively used for the application of all the above-
said drugs individually or in binary combinations in quality control 
laboratories.
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